Gwendolyn Binder-Scholl
Directeur Technique/Scientifique/R&D chez CABALETTA BIO, INC.
Fortune : 243 600 $ au 30/04/2024
Profil
Gwendolyn Binder-Scholl is an Independent Director at Instil Bio, Inc. since 2020 and the President-Science & Technology at Cabaletta Bio, Inc. since 2019.
She previously worked as the Director-Scientific Affairs at VIRxSYS Corp.
from 2002 to 2005 and as the Director-Translational Research Operations at the University of Pennsylvania from 2006 to 2011.
She also served as the Executive Vice President at Adaptimmune LLC.
From 2011 to 2019, she held the position of Chief Technology Officer at Adaptimmune Therapeutics Plc.
Dr. Binder-Scholl holds a doctorate degree from The Johns Hopkins University, which she obtained in 2002.
She completed her undergraduate studies at Wells College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CABALETTA BIO, INC.
0,04% | 04/04/2024 | 20 000 ( 0,04% ) | 243 600 $ | 30/04/2024 |
INSTIL BIO, INC.
-.--% | 16/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Gwendolyn Binder-Scholl
| Sociétés | Poste | Début |
|---|---|---|
| CABALETTA BIO, INC. | Directeur Technique/Scientifique/R&D | 01/02/2019 |
| INSTIL BIO, INC. | Directeur/Membre du Conseil | 01/07/2020 |
Anciens postes connus de Gwendolyn Binder-Scholl
| Sociétés | Poste | Fin |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 31/01/2019 |
| University of Pennsylvania | Corporate Officer/Principal | 01/01/2011 |
VIRxSYS Corp.
 VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/01/2005 |
Adaptimmune LLC
 Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Corporate Officer/Principal | - |
Formation de Gwendolyn Binder-Scholl
| Wells College | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| CABALETTA BIO, INC. | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
VIRxSYS Corp.
VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Health Technology |